TrialSignal
Clinical trial intelligence report
Phase 2 Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity (A3B1) Conjugated With the Co-stimulatory Regions 4-1BB and CD3z (ARI-0001 Cells) in Patients With CD19+ Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04778579-Jul 28, 2026
NCT ID
NCT04778579
Status
UNKNOWN
Phase
Phase 2
Sponsor
Sara V. Latorre
Executive brief
Investment-Ready Snapshot
The ARI-0001 cell therapy targets CD19+ acute lymphoid leukemia (ALL), a market with significant unmet needs, particularly among patients who are relapsed or refractory to existing therapies. The competitive landscape includes established CAR-T therapies such as Kymriah and Yescarta, but ARI-0001's unique formulation may offer differentiated efficacy or safety profiles. The trial's focus on patients not eligible for transplantation positions it well within a niche segment of the ALL market. Successful outcomes could lead to accelerated regulatory pathways and potential partnerships with larger biopharma companies seeking to enhance their oncology portfolios.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04778579
Indication
Acute Lymphoid Leukemia
Modality
small molecule
Target
Chimeric Antigen Receptor (CAR) targeting CD19 with co-stimulatory domains 4-1BB and CD3z.
Intervention
ARI-0001 cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.